Ozempic (semaglutide) targets only the GLP-1 receptor, whereas retatrutide targets multiple receptors, including GLP-1, GIP, and glucagon, which may provide more comprehensive metabolic benefits
GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation
6.5 TMAO and metabolic associated fatty liver disease MAFLD, closely linked to metabolic syndrome, T2DM, and obesity, associates with elevated TMAO
Why Ozempic Is Not Prescribed for Weight Loss at Klinic Ozempic and Wegovy, though similar due to their shared active ingredient, fulfill different medical roles
Glucagon-like peptide-1 receptor agonists were linked to a significantly higher risk for aspiration pneumonia after gastrointestinal endoscopy, particularly among those undergoing upper endoscopy and propofol sedation, according to a study